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ABSTRACT OF DISSERTATION

IT MATTERS WHO YOU LIVE WITH. THE RELATIONSHIP OF LIVING
ARRANGEMENT AND MEDICATION ADHERENCE IN PATIENTS WITH HEART
FAILURE
Medication adherence is an ongoing challenge for patients with heart failure (HF)
that can adversely affect mortality, morbidity, and quality of life. Living with a spouse
has been associated with better adherence, while living alone has been associated with
poor adherence. Other factors demonstrated to affect adherence include medication
complexity, perceived barriers to adherence, and depressive symptoms. Interestingly, the
effect of these latter factors on adherence has not been examined in the context of the
patient’s living arrangement. The purpose of this dissertation was to investigate the
relationships among medication complexity, perceived barriers, and depressive symptoms
with medication adherence across living arrangements of patients with HF using
secondary analyses of data from an HF data registry.
The first study was a secondary data analysis of 130 patients with HF and
examined the association between medication complexity and medication adherence
across living arrangements. Exploratory nonlinear regression with gamma log link was
used to determine if there was an association between medication complexity and
medication adherence, ANOVA, and Chi-square to test differences across living
arrangements. There was no association between medication complexity and medication
adherence; however, patients with HF that lived with spouses had better medication
adherence than patients that lived with non-spousal family and friends. There were a
higher number than expected participants in the group that lives with non-spousal family
or friends in the financial category that does not have enough to make ends meet.
The second study was a secondary data analysis of 209 patients with HF to
determine the association between perceived barriers and medication adherence using an
exploratory nonlinear regression with gamma log link. ANOVA and Chi-square were
used to determine differences across living arrangements. There was no association
between perceived barriers and medication adherence; however, patients with HF that
lived with spouses had better medication adherence than patients that lived with non-

spousal family and friends. The group that lived with non-spousal family or friends had
significantly higher mean depressive scores than the other two groups. There were also a
higher than expected number of participants in the group that lives with non-spousal
family or friends in the financial category that did not have enough to make ends meet.
The third study was a secondary data analysis using the same registry to
determine whether perceived social support moderates the moderation effect of living
arrangements on the association between depressive symptoms and medication
adherence. The model was significant in that depressive symptoms and two moderators
(i.e., living arrangement and perceived social support) explained 13.2% of the variance of
medication adherence. Among the predictors, the only interaction among depressive
symptoms, the living alone group, and perceived social support, significantly predicted
medication adherence. We found that a three-way interaction (X*W*Z; depressive
symptom X living arrangement X perceived social support) was significant. This
indicated that the effect of depressive symptoms on medication adherence was
significantly moderated by the living arrangement moderated by perceived social support.
This dissertation has fulfilled an essential first step in examining the living
arrangements of patients with heart failure and medication adherence. These results
suggest that living arrangements and social support should be considered in medication
adherence when planning care for patients with depressive symptoms. Future research is
needed to further examine the relationship of the group that lives with non-spousal family
and friends, and explore whether the combined intervention of improving depressive
symptoms and social support interventions focus on instrumental social support
effectively increases medication adherence.
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ARRANGEMENT, MODERATED MODERATION
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Chapter One:
Introduction
1. Medication adherence in patients with heart failure
Improving medication adherence in patients with heart failure (HF) continues to
be a challenge for clinicians and researchers. The medication adherence rate among the
6.2 million patients with HF in the United States [1] is estimated to range from 40% to
77% [2-4]. Adherence is vital because medication therapy can successfully slow the
progression of HF [5] and control symptoms [6], which contributes to emergency room
visits and hospitalizations [7] and decreases quality of life [8].
The financial costs associated with medication nonadherence related to increased
hospitalizations and emergency room visits are high. Roebuck and colleagues (2011)
examined a sample of 16,353 patients with HF from a large health insurance panel. They
found medication adherent patients had 5.72 fewer in-patient hospital days than
nonadherent patients. Lloyd and colleagues' (2019) examination of medication adherence
of Medicare recipients with HF (n=3,700,805) estimated that nonadherence was
associated with an annual cost of $5 billion of avoidable health care expenditures or
about $5000 per Medicare beneficiary [4].
Medication nonadherence is a complicated, multifactorial problem. Marital status
is one well-recognized factor associated with medication adherence [9]. Patients with HF
who are living with a spouse have better medication adherence and better HF-related
outcomes than patients living alone [9] [10, 11]. A growing number of patients in the
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United States live with non-spousal family members or friends due to changing economic
and social factors [12, 13]. Previous research has shown that caregivers perform many
medication-related tasks that promote adherence [14]. It is not known whether nonspousal caregivers are equally effective at promoting adherence as spouses. Thus, it is not
clear whether non-spousal living arrangements are similarly associated with better
adherence as spousal living arrangements.
Medication complexity includes the number of prescribed medications, the
frequency medications are taken, the various routes, and may include other specific
instructions. Most patients with HF take an average of 7 medications daily, some
multiple times, resulting in an average of 10 doses of prescribed medications per day, not
including over-the-counter medications [15]. Additionally, as they age, most patients
develop other comorbidities managed with medications that can further add to the
complexity of their regimen. Medications can be taken as injections, pills, inhalers, or
topicals, and special instructions such as take an hour before eating or with food [16] can
further complicate a medication regimen. Previous researchers examining the effects of
medication complexity and medication adherence have reported mixed findings. In
studies involving patients with chronic kidney disease and human immunodeficiency
virus, high medication complexity was associated with increased medication adherence
[17, 18]. In other studies of patients with epilepsy or other chronic diseases, high
medication complexity was associated with medication nonadherence [19, 20]. To date,
there is one study that examined if depressive symptoms moderated the relationship
between medication complexity and medication adherence [21]. A gap in the knowledge
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is if living arrangements moderates the relationship between medication complexity and
medication adherence in patients with HF.
Patients have reported multiple barriers to medication adherence [22], including
financial, social, cognitive, and practical issues unique to each patient's situation [23, 24].
Researchers have established that patients who live with spouses have more social
support to overcome barriers and improve medication adherence [9]. In contrast, patients
who live alone may not be able to overcome barriers to medication adherence due to a
lack of support [25]. Whether patients who live with non-spousal family or friends have
similar support as patients with a spouse to overcome those barriers is not known.
Depressive symptoms are present in up to 48% of patients with HF [26] and can
have a negative impact on self-care, including medication adherence [27]. Wu and
colleagues (2013) demonstrated that patients with HF and depressive symptoms were less
adherent than those without depressive symptoms. Researchers have found social support
to positively affect depressive symptoms [28] and medication adherence in patients with
HF [29]. There are multiple forms of social support [30]. Practical social support, which
includes help with medication-taking such as paying for medications, picking up
prescriptions, reading labels, filling pillboxes, and transportation, is positively associated
with medication adherence [14]. Practical support can be provided by a spouse or
someone else inside or outside the home. Structural support has been defined as marital
status or a living arrangement [31. Researchers have previously studied if structural
social support is associated with medication adherence in patients with HIV, chronic
diseases, renal transplants, diabetics, and heart failure, and in some studies, there is no
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association {De Geest, 1995 #128, 32, 33], and in other studies, there is an association
[34, 35]. Likewise, emotional support has similar findings in patients with renal disease,
HIV, and cardiac patients some studies showed that emotional support had a positive
effect on medication adherence [36]and some showed no effect [37, 38]. Marriage or
cohabitation is a very different living arrangement than living alone because the patient is
sharing a living space, resources, and optimally is a person of support and assistance if
needed. Likewise, living with an adult child is also very different than the other living
arrangements and would provide varying levels of practical support if required for
medication assistance. Perceived social support is the assessment of the support available
in someone's support network [30]. Some researchers have found that the quality of the
relationship between spouses or partners can determine whether a patient perceives good
social support [39, 40]. The quality of relationships of a patient with HF living with
people other than a spouse could have the same effect on perceived support. Although
there are many social support types, researchers generally agree they serve to alleviate
depressive symptoms to some degree in patients with heart failure [30]. How
relationships among social support, depressive symptoms, and living arrangement affect
medication adherence is not known.
In summary, multiple factors can affect adherence that may be influenced by the
living arrangement of patients with heart failure. First, while it has been shown that
patients who live alone are at higher risk for nonadherence, it is unknown whether
patients who live with non-spouses have similar adherence rates as those who live with a
spouse. Living arrangements affect the ability of patients to address the complexity of
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their medication regimen and overcome other barriers to medication adherence are also
not know. Finally, the inter-relationships among depressive symptoms, social support,
and medication adherence has not been examined.
Therefore, the purpose of this dissertation was to examine the effect of living
arrangement on the relationship of medication adherence with other factors in patients
with HF. The chapters of this dissertation represent a multi-faceted approach to
understanding factors affecting medication adherence. First, we examined if medication
complexity and the number of medications that patients with HF take interfered with
medication adherence and how that differed across living arrangements. Second, we
examined perceived barriers that may contribute to medication nonadherence and how
the effect differed across living arrangements. Third, we examined the interaction
between living arrangement and social support on the relationship of depressive
symptoms to medication adherence.
2. Summary of subsequent chapters
Chapter Two is a report of a secondary data analysis to determine the association
between medication complexity and medication adherence and differences across living
arrangements. This study addressed the scant research on medication complexity and
medication adherence in patients with HF in different living arrangements. The data were
obtained from studying the relationships of anxiety and depression with morbidity and
mortality outcomes in patients with HF [41]. Medication complexity was measured in
130 study participants using the Medication Complexity Regimen Index (MCRI), and
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medication adherence was measured using the percent of prescribed doses of an HF
medication and the days a correct number of doses were taken over three months
measured by a medication electronic monitoring system (MEMS). We used Chi-square to
test for differences across living arrangements for gender, financial status, New York
Heart Association (NYHA) functional class, and educational levels. A one-way analysis
of variance (ANOVA) with post hoc test using the least significant difference (LSD)
method was used to determine if there were differences across living arrangements
among MCRI subscores A, B, C, total MRCI score, and medication adherence.
Exploratory nonlinear regression modeling using gamma with log link was used for the
regression due to the data's nonlinear pattern.
Chapter Three is a secondary data analysis of 206 study participants using an HF
database to determine whether patients with HF self-reported barriers were associated
with medication adherence and determine group differences across living arrangements in
medication adherence, barriers, and demographic and clinical characteristics. Barriers
were measured by the 11-item Barriers subscale of the Medication Adherence Scale.
Patients rated how much of a barrier each item was to take their medication on a scale
from 0 (not an important barrier) to 10 (a very important barrier). The scores could range
from 0 to 110, with higher scores indicating more barriers to taking medications. We used
Chi-square to test for differences across living arrangements for gender, financial status,
NYHA functional class, and educational levels. Medication adherence was measured
using MEMS to assess the percent of prescribed doses of HF medication. We used
ANOVA with post hoc testing using the least significant difference (LSD) method to

6

determine if there were differences across living arrangements, medication adherence,
depression using the Brief Symptom Inventory subscale, and the barriers subscale.
Exploratory nonlinear regression modeling using gamma with log link was used for
regressions due to the nonlinear pattern of the data.
Chapter Four is a secondary data analysis using the same HF database. Data from
209 participants were used to determine whether an association between depressive
symptoms and medication adherence was moderated by living arrangement and perceived
social support in patients with HF. Living with a spouse or other family member may
represent receiving high social support levels than the living alone group. However,
having family members does not necessarily result in patients receiving helpful support.
The association between depressive symptoms and medication adherence may depend on
living arrangement and perceived social support levels. Therefore, two moderator effects
on the association between depressive symptoms and medication adherence were
examined. In this study, medication adherence was defined as the prescribed dose taken
as measured by MEMS, as in the previous studies. Depressive symptoms were measured
using the Patient Health Questionnaire-9 (PHQ-9), and social support was measured
using the Multidimensional Scale of Perceived Social Support (MSPSS). We used
perceived social support because previous researchers demonstrated it is a better
predictor of psychological well-being than objectively measured social support [42, 43].
A moderated moderation regression model was conducted using the PROCESS macro
version 3.5 (Model 3) in SPSS. The regression model included depressive symptoms as
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the independent variable, medication adherence as the dependent variable, living status as
a primary moderator, and perceived social support as the secondary moderator.
Chapter Five is a summary and synthesis of findings from the studies, including
how they contribute to medication adherence in the state of the science. Implications for
practice and future research are provided.
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CHAPTER TWO:
Examining the relationship of barriers, medication adherence, and living
arrangement in patients with heart failure
1. Introduction
Medication therapy is the mainstay of treatment for heart failure (HF). Medication
therapy optimizes cardiac function in the early stages and provides symptom relief in
later stages [44]. For the 6.5 million patients with HF in the U.S., medication adherence is
instrumental in decreasing morbidity and preventing costly hospitalizations and
readmissions [1]. Wu and colleagues (2013) have shown that medication non-adherence
in patients with HF predicts hospitalization and death. Although medication adherence is
critical in the management of HF and prevents worse outcomes for patients with HF,
medication adherence has been reported to range from only 40-60% in patients with HF
[2, 3, 45, 46].
2. Background
Medication non-adherence, in general, is a long-standing problem [47]. The
problem is particularly persistent in HF [48, 49]. To develop effective strategies to
combat medication non-adherence, researchers have identified demographic and
psychosocial factors (e.g., being married, perceived social support, and financial status)
related to medication adherence [50, 51]. An under-explored factor that may be very
important in predicting medication non-adherence is medication complexity [52].
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Medication complexity is a concept that encompasses the number of medications
that a patient takes (prescription and over-the-counter), multiple dosage forms, (e.g.
inhaler, insulin via a syringe, and capsule), frequency of dosing (twice a day, three times
a day), and additional usage directions (e.g. sit up for 5 hours after taking). The findings
from the few studies of medication complexity among patients with HF on medication
adherence have been inconsistent. Dolansky and colleagues (2016) found in 309 elderly
outpatients with HF that medication adherence measured with an electronic pillbox was
not related to medication complexity, which was measured using the Medication
Complexity Regimen Index (MCRI) [52]. In contrast, Goldstein et al. (2017) also
measured medication adherence with an electronic pillbox and found that higher
medication complexity scores, using the MCRI, were associated with higher rates of
medication non-adherence [21]. This finding fits with those of Colavecchia and
colleagues (2017), who found that higher medication complexity scores using the MRCI
were associated with 30-day rehospitalization in patients with HF controlling for all other
factors. These conflicting findings may result from failure to consider important
moderators of the relationship between medication complexity and medication adherence
[7].
Given the consistency of the relationship of social support with medication
adherence, it may be an important moderator. Researchers have established that family
and friends, in providing social support, perform several medication-related activities for
patients (Noureldin, 2017). This type of social support is defined as the health-promoting
instrumental assistance that individuals receive from family members and friends [53].
10

For patients with HF who live alone, instrumental social support is often lacking. For this
reason, the patient's living arrangement may be fundamental when considering the
relationship between medication complexity and medication adherence. Therefore, the
purposes of this study were to determine the following: 1) whether medication
complexity and medication adherence differ by living arrangement; 2) whether
medication complexity is associated independently with medication adherence, and 3)
whether living arrangement (i.e., living with a spouse or cohabiting; living with a nonspousal family member or friend; or living alone) moderates any association between
medication complexity and medication adherence in patients with HF.
3. Methods
3.1.Design, Sample, and Setting
This was a secondary data analysis from a study of mechanisms for the
relationships of anxiety and depression with morbidity and mortality outcomes in patients
with HF [41]. After institutional review board approval, explanation of the study, and
receipt of a signed consent form, patients were enrolled from outpatient cardiology
clinics in an academic medical center in a southern state. Eligible participants had a
confirmed diagnosis of chronic HF, were optimized on medications before enrollment,
had no terminal illnesses, were in New York Heart Association (NYHA) functional class
II to IV, and had no cognitive impairment. We selected 133 patients with HF from the
parent study for data analysis who had complete data on key variables, including
medication adherence, medication lists, age, gender, living arrangements, and ethnicity.
4. Measures
11

4.1. Medication adherence was defined in this study as (1) the percent of
prescribed doses of a HF medication taken over three months measured by a medication
electronic monitoring system (MEMS), (2) the percent of correct days of doses taken
over three months measured by MEMS. This monitoring device in the cap of the
medication container records each time the medication bottle is opened, indicating that
the medication's dose was removed. Each MEMS bottle contained one of the following
medications: beta-blocker, an ACE inhibitor, or a diuretic. Previous studies have
demonstrated that observing one medication adherence is a representative indicator of allmedication consumption by patients [54, 55]. The MEMS is considered the gold standard
for indirect medication adherence [56].
4. 2. Medication complexity was assessed using the Medication Regimen
Complexity Index (MRCI) [16]. The MRCI consists of 3 sections (i.e., dosage form,
dosage frequency, and complexity of instructions), with each section representing a
different facet of medication complexity. Weights are assigned to each aspect of the
medication regimen.
In Section A, dosage forms, weights can range from 1 to 5, with tablets and
capsules representing the simplest dosage form and thus receiving a weight assignment of
1. More complex forms of medication delivery, such as medications that must be drawn
up in a syringe from a vial, are weighted as a 4 unless prefilled. A weight of 3 is assigned
to prefilled syringe dosage forms. Dialysate delivered at home (peritoneal form) is
weighted a 5. The weights of the dosage types are added together and totaled for Section
A.
12

In Section B, dosage frequency, weights can range from 0.5 to 12.5. Once a day,
dosing is given a weight of 1, higher weights are assigned to medications that are
prescribed multiple times a day, and 0.5 weight given to medicines that are taken "as
needed." Every two-hour dosing receives a weight of 12.5. Each medication is assigned a
weight, and the assigned weights in this section are totaled.
In Section C, the complexity of instructions, weights can range from 1 to 2. A 1 is
assigned to relatively simple instructions, such as, "if you have chest pain, put under your
tongue." A 2 is assigned to additional instructions that may complicate the medication
regimen, such as taking medication with food or a particular time of day. Weights are
assigned to each medicine, and this section is also totaled.
Once all sections are scored, all three sections' total scores are summed for a total
medication complexity regimen score. The lowest possible score is zero for those taking
no medications, and there is no defined upper limit of the score of this instrument because
of the large number and types of medications patients may take. The instrument's face
and content validities were initially established by eight pharmacy experts [16]. Further,
more in-depth validity has been [45] established, and the instrument has been used and
performed well in multiple studies [57, 58].
4.3. Living arrangement was defined as patients' living arrangements with
others. Living arrangement was self-reported at baseline as to who the patient lives.
Living arrangement was categorized as follows: 1) living with a spouse or cohabiting; 2)
living with a non-spousal family member or friend, or 3) living alone.
13

4.4. Other variables of interest. Patient demographic information included age,
gender, race, education, financial status and the Patient Health Questionnaire-9, a
measure of depressive symptoms. Comorbidities were quantified using the Charlson
Comorbidities Index [59]. The comorbidity index is preferable to a simple comorbidity
count because it weighs the comorbidities by effects on mortality, where conditions
projected to have greater lifespan reduction are given more weight. New York Heart
Association (NYHA) functional class was determined by research nurses from the patient
interview. Data were collected from the patient interview and medical record.
5. Procedure
A research nurse determined patient eligibility and explained study requirements
to eligible patients and obtained written consent. Patient sociodemographic and clinical
characteristics were collected by interview and review of the medical record at baseline.
Study subjects were then provided written and verbal instructions about using the MEMS
bottle, which medication to put in the bottle and closing the cap after each use. A MEMS
diary was provided to record all unscheduled MEMS caps openings so they could be
removed from the analysis, so nonadherence was not over-reported. Patients returned the
MEMS bottle after three months of daily use of the MEMS device. The MEMS data were
downloaded and transferred into a database for analysis. Unscheduled cap openings were
excluded from the analysis based on the diary entries
6. Data Analysis
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All data analysis was performed using SPSS (Chicago, IL), version 27.0; a pvalue of .05 indicated significance. Patient characteristics were summarized using means
and standard deviations or frequency distributions. Before conducting analyses, missing
data were examined. Two participants were excluded because they reported no
medications; however, they had MEMS data. We used listwise exclusion of these
individuals' missing data. Patient characteristics were compared using analysis of
variance (ANOVA) or chi-square as appropriate to the level of measurement.
Specific aim 1, to determine if there are group differences across living
arrangements in medication complexity and medication adherence (measured as the
percent of doses taken and percent number of days correct doses taken), was assessed
using one-way ANOVA. Total medication complexity score and the three medication
subscores (A, B, and C) were compared among the three living arrangement groups. Posthoc analyses, when there was a significant difference among the groups, was conducted
using the least significant difference (LSD) method.
For specific aim 2, the independent association between medication complexity
and medication adherence was assessed with nonlinear regression using gamma with log
link. We used nonlinear regression because the data did not meet the assumption of linear
regression that there is a linear relationship between the continuous level independent
variables and the dependent variable. Independent variables were age, living
arrangements, financial status, comorbidities, and medication complexity. The dependent
variable was medication adherence. We were unable to assess specific aim three because
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we did not find an association between medication complexity and medication adherence;
thus, we could not perform a moderation analysis.
7. Results
7.1 Sample characteristics
A total of 130 participants were included in the study (Table 1). The sample was
divided into three groups based on living arrangements: 1) living with a spouse (n=69,
53%), 2) living alone (n=39, 30%), 3) and living with a non-spousal family or friend
(n=22, 18%). Most of the participants were Caucasian (90%) and male (70%). The
average age of participants was 61 years old (SD=11.5). A quarter of the sample had less
than a high school education, 26% had a high school education, 32% had some college,
and 17% had a college degree or above. For financial status, 54% reported having enough
finances to make ends meet, with 24% reporting that they live comfortably, and 22%
reporting they do not have enough to make ends meet. Slightly over half of this sample
was classified in NYHA functional class III/IV (61%), the mean Charlson Comorbidity
Index score was 3.3 (SD=1.7), and the mean depressive symptom score was 6.9
(SD=5.9).
The mean number of medications participants were taking was 6.3 (SD=1.9). The
MRCI subscore A mean, which represents total dosage forms, was 1.8 (SD=1.5). The
MRCI subscore B mean, which represents the frequency of medications taken, was 7.1
(SD=2.2). The MRCI subscore C mean, which represents additional directions to take the
medications, was 0.13 (SD=.34). The mean MRCI score for the sample was 8.9
16

(SD=3.3). The adherence level for the prescribed number of doses taken was 88.6 (SD =
15.7) %, and for the days, the correct number of doses taken was 80.6 (SD = 22.8) %.
7.2 Sample characteristics compared among the living arrangement groups
We compared demographic and clinical information of participants by living
arrangements (Table 1). There were no differences among the groups in age, gender,
race, education, NYHA functional class, Charlson comorbidity, or depressive symptom
levels. Financial status did differ among the groups. In testing financial status across
living arrangements, patients who lived with non-spousal family or friends had a higher
than expected number in the category, 'not having enough to make ends meet'
(χ2(4)>=15.0, p=0.006).
7.3.Medication complexity scores and medication adherence rates compared
among living arrangement groups
We compared medication adherence rates, MRCI score, MRCI sub-scores, and
the number of medications taken by living arrangements (Table 2). There were no
differences in total MRCI score, medication complexity subscore A, B, C, or the number
of medications taken by living arrangements. There were, however, differences observed
in medication adherence rate for percentage of the prescribed number of doses taken
(p=0.04) and percentage of days correct doses were taken (p=0.03). The group who lived
with their spouse had a higher percentage of doses taken than the group who lived with
family or friend (92 ± 9.8% vs. 80 ± 24.5%; p = 0.004). Likewise, the group who lived
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with their spouse also had a higher percentage of days of correct doses taken (85 ± 16.5%
vs. 71.7± 30.1%; p = 0.03) than the group who lived with non-spousal family or friend.
7.4. Association between medication complexity and medication adherence
For the nonlinear regression analyses predicting medication adherence measured
as the percent of prescribed doses taken, we entered age (B=.002, p=.332), comorbidity
(B=.-.021, p=0.979), living arrangements (lives with spouse- B=.0.067, p=0.172, lives
with non-spousal family or friend- B=.-.088, p=0.916), financial status (comfortable,
enough to make ends meet- B=-.005, p=.936, have enough to make ends meet- B=.-.041,
p=.067) and MRCI total score (B=.005, p=0.487) into the model. There were no
significant predictors in the model (Table 3). We also conducted backward removal of
variables, and again, there were no significant predictors of medication adherence.
Using the percent of days, the correct number of doses were taken as an indicator
of adherence, we conducted a nonlinear regression analysis using the same variables as
we did in the previous model. We had a similar result with no significant findings, as
follows: age (B=.006, P=0.098), Charlson comorbidity (B=-.037, P=.110), living
arrangement (lives with spouse- B=.137, P=.103, lives with non-spousal family or friendB=-.002, P=.986), financial status (comfortable, enough to make ends meet- B=-.069,
P=0.654, have enough to make ends meet- B=-.042, P=.654), and MRCI (B=0.004,
P=0.738).

8.

Discussion
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We did this study to determine whether medication complexity was associated
with medication adherence and whether living arrangements moderated any relationship
between medication complexity and medication adherence in patients with HF. We did
not find an association between medication complexity and medication adherence and
could not test our moderation hypothesis.
One explanation for the lack of association of medication complexity with
medication adherence could be the low rate of medication complexity in our sample and
the high rate of medication adherence. We found an 89% overall medication adherence
rate in this sample. Before discussing possible reasons for a low rate of medication
complexity, we want to point out these findings are similar to a study of 157 patients with
stage 5 chronic kidney disease [17]. These researchers reported an 83% medication
adherence rate measured by self-report using the 8-item Morisky Medication Adherence
Scale. The mean MRCI score in that study was 22.8 (SD=7.7), which was substantially
higher than the mean score in our sample, yet, they also found no association between
medication adherence and complexity [17]. In contrast, Goldstein, and colleagues (2017)
used an electronic pillbox to measure medication adherence in 299 patients with HF, and
they found a significant relationship between MRCI and medication adherence. However,
they did not report the mean score of the MRCI for the sample, so we could not compare
their sample with ours on that measure. Our medication adherence rate was higher than
theirs (mean=89% vs. 73.57%), but without knowing the MRCI scores, it is difficult to
make a comparison.
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Possible reasons for low MRCI scores for this study include providers' prescribing
pattern in this area. Our study's mean MRCI score was low compared to other medication
complexity scores cited in HF studies in the literature [60, 61]. The mean number of
medications taken by our sample was less than or equal to other HF studies in the
literature [62, 63]. Our sample findings could be due to the multi-disciplinary team
approach taken at the academic medical center where our study participants were
recruited. Clinical pharmacists are employed to work with providers in the cardiac
clinics. The pharmacists review patients' medications and make recommendations to
providers, in addition to educating patients. Previous researchers have demonstrated that
clinical pharmacists increase medication adherence in HF patients by reducing barriers to
medications such as finding lower-cost alternative medications when possible,
simplifying regimens and patient education [64-66].
Another explanation for the high medication adherence rate could be that most of
our sample lived with a spouse or a partner. Researchers have previously demonstrated
that spousal social support is associated with medication adherence [9]. We found a lower
rate of medication adherence in the group who lived with non-spousal family and friends
than in the group who lived with spouses. There were no differences found between the
group who lived alone and the other two groups. One possible explanation is that even
though a patient lives with a non-spousal family or friend, they likely do not receive the
same social support level one receives from a spouse.
Another finding in the group who lived with a non-spousal family or friend was
that financially, they had a higher rate of participants who did not have enough to make
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ends meet, compared to the other two groups. Socioeconomic factors have been
recognized as a barrier to medication adherence in previous literature [13, 67, 68] and
may also explain why this group had lower medication adherence rates than the living
with spouse group.
9. Limitations
Although we included 130 patients with HF and objectively measured medication
adherence, this study may have not been adequately powered to demonstrate existing
associations. This being a secondary data analysis limits the available measures from the
parent study. Our findings have some limits to generalizability due to the homogenous
demographic makeup of our sample. While computing the MRCI retrospectively, at
times, questions arose, and ideally, being able to check with the patient or a pharmacist
about the medication(s) would have been optimal.
10. Conclusion.
Even though the moderation analysis could not be conducted, our findings are
unexpected, and this study does not solve the controversies related to medication
complexity, medication adherence, or living arrangements in patients with HF. To do so,
future studies need to include larger sample sizes with attention to ensuring adequate
power. Moreover, samples with substantial heterogeneity in medication adherence rates
and medication complexity scores need to be recruited. A future large prospective study
is warranted.
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This study's results have important implications for clinicians and researchers
who work with patients who have HF. Due to the importance of medication adherence to
maintain optimal control of HF symptoms and reduce complications related to
polypharmacy and pill burden, the examination of medication complexity deserves
further research in this population. A patient's living arrangement may serve as a buffer
or risk factor to medication adherence, and medication complexity may play a role in
medication adherence in patients’ with HF, but further research with a larger sample size
will be required before answering that question. This study replicated what other studies
have found previously in that patients with HF have a high pill burden, but despite that, in
this sample, the medication adherence rate remained high. Adherence was highest for
those living with a spouse and lowest for those who lived with a non-spousal family
member or friend. There was no difference in medication adherence rates between the
living alone group and the other groups. Researchers can use the results of this study to
determine reasons for lower medication adherence in the group who lives with nonspousal family members or friends and could and could develop and test interventions to
promote better adherence.
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Table 2.1. Characteristics of the sample of patients with heart failure (n=130)
Variable

Age, years
Male gender

Total sample
N=130

Living with spouse
n=22

N (%) or Mean ± SD
61 ± 11.3
61 ±11.9
90 (70)

53 (77)

Living with nonspouse family
n= 22

Living alone
n= 39

p

58.± 12.7

62.6 ±10.7

0.295

12 (55)

25 (64)

0.95

Race

0.317
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Caucasian

116 (89)

66 (96)

16 (73)

34 (87)

African American

14 (11)

3 (4)

6 (27)

5 (13)

Education
Less than high school
graduation

32 (25)
34 (26)

16 (23)
21 (30)

8 (36)
3 (14)

8 (21)
10 (26)

High school graduate

41 (32)
22 (17)

18 (26)
13 (19)

9 (41)
2 (9)

14 (36)
7 (18)

Some college
College graduate or above

0.292

Table 2.1. Characteristics of the sample of patients with heart failure (continued)

Financial status
Lives
comfortably

31 (24)

21 (30)

4 (18)

6 (15)

Enough to
make ends meet

70 (54)

37 (54)

7 (32)

Do not have
enough to make
ends meet

29 (22)

11 (16)

11 (50)

31 (45)
38 (55)

7 (32)
15 (43)

13 (33)
26 (66)

0.57

Charlson
3.1±1.7
comorbidity index
score

3.2 ±1.4

3.1 ±1.4

3.6 ±1.6

0.262

Patient health
questionnaire-9
score

6.3 ±5.8

9.6 ±6.3

6.9±6.0

0.069

0.006

26 (66)
7 (18)

24
NYHA functional
class
III-IV

I-II

51 (39)
79 (61)

6.9 ±5.9

Table 2.2 Comparison of medication complexity and medication adherence among three living arrangement groups
Variable

Total

Lives with

sample

spousea

N = 130

n = 69

Lives with
non-spousal
family or
friendsb

Lives
alonec
n = 39

F
(2,127)

LSD
post-hoc
test,

value

P <.05

n = 22
M ± SD

M ± SD

M ± SD

M ± SD

p

Subscore A- dosage forms

1.8±1.5

1.6 ± 1.3

1.7 ± 1.4

2.1 ± 1.8

1.34

0.265

Subscore B- dosing frequency

7.1±2.2

7.0 ± 2.2

7.1 ± 1.9

7.4 ± 2.5

0.327

0.722

Subscore C- additional
directions

0.13±0.34

0.1 ± 0.3

0.14 ± 0.35

0.20± 0.40

1.11

0.331

Total score

8.9±3.3

8.8 ± 2.7

9.1 ± 3.3

9.4 ± 3.8

1.14

0.323

Number of medications

6.3±1.9

6.5 ± 2.1

6.3 ± 1.9

6.2± 1.8

0.047

0.699

Prescribed number of doses taken
(%)

88.6±15.7

92.2 ± 9.9

80.1 ± 24.5

87.4 ± 16.0

5.8

0.004

a>b

Days correct number of doses
taken (%)

80.6±22.8

85.1 ± 16.5

72.0 ± 31.0

78.0 ± 25.2

3.7

0.028

a>b

Medication complexity:
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Table 2.3. Summary of nonlinear regression analysis predicting medication adherence measured as the percent of prescribed
doses taken
Predictor

B

SE

p

OR

95% CI

Total medication regimen complexity index
score

0.005

0.0068

0.487

1.005

(0.991, 1.02)

Living with spouse

0.067

0.049

0.172

1.070

(0.971, 1.79)

Living with non-spousal family or friend

-0.088

0.065

0.175

0.916

(0.807, 1.04)

Living arrangement
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Lives alone (reference group)

1

Comorbidity

-0.021

0.013

0.091

0.979

(0.955, 1.00)

Age

0.002

0.002

0.332

1.00

(0.998, 1.006)

Comfortable, have enough to make ends meet

-0.005

0.069

0.936

0.995

(0.870,1.14)

Have enough to make ends meet

-0.041

0.055

-0.150

0.067

(0.861, 1.07)

Financial status

Do not have enough to make ends meet
(reference group)
Note. CI= confidence interval for odds ratio (OR); SE = standard error

1

Table 2.4. Summary of nonlinear regression analysis predicting medication adherence measured as the percent of days correct
number of doses were taken
Predictor

B

SE

p

OR

95% CI

Total Medication Regimen Complexity Index
score

0.004

0.012

0.738

1.004

(0.981, 1.03)

Living with spouse

0.137

0.084

0.103

1.15

(0.973, 1.35)

Living with non-spousal family or friend

-0.002

0.111

0.986

0.998

(0.803, 1.24)

Lives alone (reference group)

0

Comorbidity

0.110

0.023

0.110

0.964

(0.921, 1.01)

Age

0.098

0.023

0.098

1.01

(0.999, 1.01)

Comfortable, have enough to make ends meet

-0.069

0.116

0.549

0.933

(0.743,1.17)

Have enough to make ends meet

-0.042

0.093

0.654

0.959

(0.798, 1.15)

Do not have enough to make ends meet
(reference group)

0

Living Arrangement

1

27

Financial Status

Note. CI= confidence interval for odds ratio (OR); SE = standard error
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CHAPTER THREE:
Examining the relationship of barriers, medication adherence, and living
arrangement in patients with heart failure
1. Introduction
There are 6.5 million patients in the United States with heart failure (HF) [1]. HF
is a disease managed primarily by medication therapy, and thus medication adherence is
vital to avoid morbidity and costly hospitalizations [69]. In 2014, the estimated costs of
HF-related hospitalizations were $ 11 billion [70]. Researchers report the rate of
medication adherence to be between 38-60% in patients with HF [46, 71]. Despite
knowing that medication adherence is an essential part of their disease management,
patients have reported several barriers that interfere with taking their medications as
prescribed [22].
2. Background
A few researchers have delineated barriers into perceptual barriers, such as
attitudes and beliefs, and practical barriers, such as forgetfulness or medication frequency
[72]. Perceptual factors arise from the consciousness related to medication adherence,
and Horne and colleagues (2019) classify this as intentional processes. Conversely,
ability, or capability, they classify as an unintentional process related to medication
adherence. [73]. The theory that these concepts are derived from is called the Perceptions
and Practicalities Approach (PAPA), and it is based on an extended version of the
Common-Sense Model [73]. This framework has similarities to the theories that Wu and
colleagues (2008) used to design their Medication Adherence Scale that is used in this
study.
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Wu and colleagues (2008) used a theory-based approach to develop the
Medication Adherence Scale based on the Theory of Planned Behavior (TPB) and the
Health Belief Model (HBM). Like PAPA, the HBM also includes the patients'
perceptions of the susceptibility of illness, perception of treatment, perception of the
severity of the disease, the perception of the therapy's payoff must outweigh the patient's
perceived barriers to act. There are also cues in the model that can motivate the patient to
act. [74]. In the TPB, attitudes, subjective norms, and perceived behavioral control
impact a patient's behavioral intention, affecting their behavior [75].
Horne and colleagues (2019) assert that it is easier to change a practical barrier
related to medication adherence than it is to change a perceptual one. In line with this
thinking, one's living arrangement may help or hinder practical issues such as
forgetfulness or lack of ability or capability, such as driving to the pharmacy or filling a
pillbox. Previous research has demonstrated that married patients have better medication
adherence than patients who live alone [9]. However, not everyone lives with a spouse or
a partner. Due to socioeconomic hardships, many older adults live with other family
members, friends, or adult children [13]. It is not known whether this living arrangement
helps overcome practical to medication adherence.
Further, DiMatteo (2004) and Gallagher and colleagues (2011) demonstrated that
social support is an important factor in medication adherence for patients with HF. Living
with a spouse provides a social support level that fosters self-care and improves
medication adherence [9, 76]. Less is known about how living with a non-spouse affects
medication adherence.
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Therefore, the purpose of this study was to determine whether: 1) self-reported
barriers to medication adherence differ by living arrangement; 2) self-reported barriers is
associated independently with medication adherence, and 3) living arrangement (i.e.,
living with a spouse or cohabiting; living with a non-spousal family member or friend; or
living alone) moderated the association between barriers and medication adherence.
3. Methods
3.1.Design, Sample, and Setting
This was a secondary data analysis using data from a prospective, longitudinal
study of objectively measured medication adherence in patients with HF. Patients were
recruited from an academic medical center in a southern state. Demographic, clinical, and
psychosocial data were collected by questionnaires and medical record review for
patients with HF.
Patients enrolled from outpatient cardiology clinics were eligible if they 1) had
confirmed diagnoses of chronic HF 2) were optimized on their medical therapy for at
least one month before enrollment, 3) had no coexisting terminal condition, and 4) were
in New York Heart Association (NYHA) functional class II to IV. The sample was
divided into three groups based on living arrangement 1) married and living with a
spouse or partner (n=124, 53%), 2) living with a non-spouse, family or friend (n=45,
19%), and 3) and living alone (n=63, 27%)
4. Measures
4.1. Living arrangements were defined as 1) married and living with a spouse or
cohabiting with a partner, 2) living with a non-spousal family or friend, 3) living
alone.
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4.2. Medication adherence was defined as the percent of prescribed doses of HF
medication taken over three months, measured by a medication event monitoring system
(MEMS). A microelectronic monitoring device in the cap of the medication container
records each time the bottle is opened, indicating a dose of the medication was removed.
Each MEMS bottle contained one of the following medications: beta-blocker, an ACEinhibitor, or a diuretic. Previous researchers have provided evidence that MEMS is a
reliable and valid measure of medication adherence [56]. Researchers have also shown that
using one medication in a MEMS system is adequate to determine all-medication
adherence by patients [54, 55].
4.3. Barriers. Patients completed the Medication Adherence Scale at baseline.
Barriers were measured by the 11-item Barriers subscale of the Medication Adherence
Scale. [75]. Perceptual barriers, which include beliefs and attitudes towards taking
medications, and practical issues like ability and capability were included in the barrier
subscale of the Medication Adherence Scale [46, 67]. The instrument has three subscales
assessing knowledge, attitudes, and barriers. Using this instrument, the researchers
demonstrated that barriers could determine medication-taking behaviors in patients with
HF [22]. The barriers subscale included questions about beliefs about symptoms and the
efficacy of taking the medication. The barrier subscale also contained questions about
practical issues such as the cost of medications, available social support, forgetfulness,
and issues such as taking medication when the patient leaves the house. Patients rated
how much of a barrier each item was to take their medication on a scale from 0 (not an
important barrier) to 10 (a very important barrier). The scores can range from 0 to 110,
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with higher scores indicating more barriers to taking medications. The Barriers subscale
was found to be reliable (Cronbach's alpha=.94) in a population with HF [22].
4.4. Depressive symptoms were measured by the Brief Symptom Inventory
depression subscale (BSI). The BSI consists of 6-items, each rated on a 5-point Likert
scale of 0= not at all, 1= a little bit, 2=moderately, 3= quite a bit, and 4= extremely. The
BSI depression subscale assesses patient experiences of depressed mood, loss of interest,
vulnerability to criticism, loneliness, worthlessness, hopelessness, and suicidal thoughts.
The score is the average of the total of the six items, with higher scores indicating greater
depressive symptoms.
4.5. Comorbidities. We used the Charlson comorbidity index to assess
comorbidity. This instrument is useful because it weighs the comorbidities by effects on
mortality, where conditions projected to have greater lifespan reduction are given more
weight [59].
4.6. Other variables included age, gender, NYHA functional class, financial
status, and education level measured by patient interviews and medical record reviews.
5. Procedure
Permission for this study was obtained from the University of Kentucky Medical
Institutional Review Board. A trained research nurse confirmed patient eligibility. The
research nurses explained the study requirements to eligible study subjects, obtained
informed consent, and arranged for the baseline assessment. Patients completed the
Medication Adherence Scale, Charlson comorbidity scale, assessed the NYHA functional
class, and the BSI at baseline. Detailed written and verbal instructions were given for
using the MEMS bottle. Patients were provided with a medication diary to record
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unscheduled cap openings, bottle refills, or if opened by accident without taking a pill.
These events were excluded from data analysis. Patients who used pillboxes were asked
to keep the MEMS bottle next to their pillbox and open the cap when medicines were
taken from the pillbox. MEMS data were printed, compiled, and entered SPSS for further
analyses.
5.1 Data Management and Analysis
All data analysis was performed using SPSS (Chicago, IL) version 27.0. Patient
characteristics were summarized using means and standard deviations or frequency
distributions. Patient characteristics were compared using analysis of variance (ANOVA)
or chi-square as appropriate to the level of measurement.
Specific Aim 1. One-way ANOVA determined differences in perceived barriers
and medication adherence across living arrangement groups. Post-hoc analyses were
conducted using the least significant difference method.
Specific Aim 2. The independent association between perceived barriers and
medication adherence was determined by nonlinear regression with gamma with log link.
We used nonlinear regression because the data did not meet the assumption of a linear
relationship between the continuous level independent variables and the dependent
variables. Independent variables were age, gender, living arrangement, financial status,
depressive symptoms, and barriers.
Specific Aim 3. We could not perform a moderation analysis because we did not
find an association between barriers and medication adherence.
6. Results
6.1 Patient Characteristics
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A total of 206 patients with HF had complete MEMS data and were included in
the analysis (Table 1). Most of the participants were Caucasian (90%) and male (70%)
with an average age of 61 years (SD=12). There were more patients in New York Heart
Association functional class III/IV (57%) than functional class I/II, 43%). Most of the
patients reported having enough money to make ends meet, with only 20% (n=46)
reporting not having enough money.
There were no group differences in age, gender, NYHA functional class, or
Charlson comorbidity index among the three groups. There were more than expected
Caucasians in the group living with a spouse (χ2(4) ≥18.27, p=0.001). In the group living
with non-spousal family or friend, there were less than expected Caucasians and more
than expected African Americans (χ2(4) ≥18.27, p=0.001).
6.2 Medication barriers and medication adherence rates
There were no group differences in medication barrier scores (mean=19.7,
SD±28.7). Patients living with their spouse had a higher rate of medication adherence
(mean=93%, SD±9.4) than patients living with a non-spousal family or friend
(mean=86%, SD±20.6). The group living alone did not differ from either group in barrier
scores or adherence rates.
Depressive symptom scores were significantly higher in the group living with nonspousal family or friend than the group living with the spouse group. Scores of the group
living alone did not differ from the other two groups.
6.3. Association between medication barriers and medication adherence
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For the nonlinear regression analyses predicting medication adherence, after
controlling for age, gender, comorbidity, living arrangement, and financial status, the
overall regression model and the variable of interest was the barriers score (B=-.001,
p=0.260), and the overall regression model was not significant. There were no significant
predictors in the model (see Table 2). There were also no significant predictors of
medication adherence when the regression was run with backward removal of variables.

7. Discussion
We were not able to determine whether living arrangement moderated the
relationship between medication barriers and medication adherence because there was no
association between barriers and adherence. One explanation for the lack of association
could be the high average medication adherence rate of 90%. In addition, the average
barrier score was in the lower 20% of the possible range of scores, indicating that as a
group, the patients did encounter barriers to taking medication. The use of clinical
pharmacists in the clinics the patients were recruited from may have played a role in low
barrier scores. Researchers have demonstrated that clinical pharmacists work with
patients to identify ways to overcome medication adherence barriers such as simplifying
dosing, finding affordable medication options, and arranging for automatic refilling and
home delivery [64, 65].
Interestingly, the group living with a non-spousal family or friend had the lowest
medication adherence rates among the groups but had similar barriers scores suggesting
other factors contributed to the lower adherence rate. The group living with a non-spousal
family or friend had a higher number of participants reporting not having enough money
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to make ends meet and significantly higher BSI depressive scores than the other groups.
Prior researchers reported an association between lower socioeconomic status and
depressive symptoms [77.]. Both depressive symptoms [21, 27] and lower socioeconomic
status have been associated with decreased medication adherence [67, 78]. [79, 80]. In
part, these findings may explain why the group living with a non-spousal family member
or friend had lower adherence rates.
The relationships among the household members may also play a role. Weimers
and colleagues (2017) reported that adult children living in households with their mothers
primarily benefited from living arrangements due to a lack of economic resources. In this
study, we did not assess the non-spousal relationship of who the patients were living
with; in future studies, asking about the relationship may provide more information,
leading to targeted interventions.
8. Limitations
We included 206 patients with HF and objectively measured medication
adherence; this study may not have had adequate power to find an association because we
did not have enough participants in all living arrangements groups. This being a
secondary data analysis limits the available measures from the parent study. Assessing
health literacy as another way of measuring skills related to medication taking would
have provided insight into a barrier that has been associated with medication adherence
[72]. Additionally, the medication formulation, such as giving injections or cutting pills
or the ability to open containers, has been documented as a barrier that is not on the
barriers instrument [72]. There are other barriers measures available that focus on
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practical barriers rather than Our findings have some limits to generalizability because
our sample was predominantly Caucasian and male.
9. Conclusions
We found a difference in the medication adherence rate in the group of patients
who lived with nonspousal family or friends compared to the group that lived with
spouses. There were no differences among the groups for barriers to medications. When
looking at other variables, we found a difference in the group's financial category that
lives with nonspousal family or friends and the other groups. We also found that group
had higher depressive scores on the BSI than the other groups.
We could find no association between barriers to medications and medication
adherence, and thus we were unable to conduct a moderation analysis using living
arrangements. A future study that includes a sample with substantial heterogeneity in
medication adherence rates and living arrangements need to be recruited. A future large
prospective study to test an instrument that focuses on practical barriers is easier for
interventions than changing attitudes or motivation about medication adherence [72].
Testing this validity of this instrument, and then designing interventions to overcome
barriers based on patient feedback.
The results of this study have important implications for clinicians and
researchers who work with patients with HF. We found that patients that lived with a
spouse had the highest medication adherence, and patients that lived with non-spousal
family or friends had the lowest. This group also had the most members that financially
did not have enough to make ends meet. Thus, a patient's living arrangement and
financial status may hinder or help with medication adherence. Researchers should direct
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future studies to determine lower medication adherence in patients who live with nonspousal family or friends. The nature of the relationships among household family
members should also be explored to determine interventions to promote better adherence
tailored to patient needs.
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Table 3.1. Clinical and demographic characteristics
Variable
Total sample
Living with spouse
N=206
n= 110

Living with nonspouse family
n= 40
N (%) or Mean ±SD

Living alone
n=56

p
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Age, years

60.1±12.0

59.8±11.5

57. 5±14.4

62.6±9.9

0.103

Gender
Female
Male

74 (36)
132 (64)

31 (15)
79 (38)

21 (10)
19 (9)

22 (11)
34 (16.5)

0.103

Race
Caucasian
AfricanAmerican
Asian

176 (85)
27 (13)
3 (2)

101 (49)
6 (3)
3 (1)

28 (14)
12 (6)
0 (0)

47 (23)
9 (4)
0 (0)

0.001

89 (43)
117 (57)

54 (26)
56 (27)

15 (7)
25 (12)

20 (10)
36 (17)

0.186

New York
Heart
Association
functional class,
I-II
III-IV

Table 3.1. Clinical and demographic characteristics (continued)
Financial Status.
More than
enough to
make ends
56 (28)
36 (17)
meet.
Enough to
make ends
meet.
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Not enough
to make ends
meet.
Education
Less than
high school
High school
graduate
Some college
College
graduate or
above
Medication
barriers
Charlson
comorbidity index

107 (52)

42 (20)

56 (27)

18 (9)

6 (3)

14 (7)

19 (9)

32 (16)

14 (7)

0.037

10 (5)

44 (21)

20 (10)

11 (5)

13 (6)

55 (27)

29 (14)

10 (5)

16 (8)

60 (29)

29 (14)

15 (7)

16 (7)

44 (22)

32 (16)

1 (.005)

11 (5)

.413

19.7±28.7

16.1±25.7

25.7±32.5

22.6±30.9

0.130

3.4 ±1.9

3.2 ±1.8

3.3 ±1.8

3.8 ±1.8

0.136

Table 3.1. Clinical and demographic characteristics (continued)
Variable
Brief symptom
Inventorydepressive
symptoms
scale
Medication
adherence

Total sample
N=206

Living with nonspouse family
n= 40
1.00±1.02

Living alone
n=56

p

0.727±0.830

Living with
spouse
n= 110
0.609±0.742

0.767±0.830

0.035

90.6 (13.9)

93.0 (9.4)

86.0 (20.6)

89.1 (14.6)

0.014
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Table 3.2. Summary of nonlinear regression analysis predicting medication adherence
Predictor

B

SE

p

OR

95% CI

Medication barriers

-0.001

0.001

0.260

0.999

(0.999, 1.00)

Living with spouse

0.037

0.032

0.254

1.038

(0.974, 1.106)

Living with non-spousal family or friend

-0.024

0.041

0.560

0.976

(0.900, 1.059)

Comorbidity

-0.006

0.0071

0.392

0.994

(0.098, 1.008)

Age

0.001

0.0013

0.409

0.999

(0.999,1.004)

0.014

0.0424

0.744

1.014

(0.933, 1.102)

0.009

0.0357

0.804

1.009

(0.941, 1.082)

Lives alone (reference)
42

How well your household lives on its
income, financially:
Comfortable, have enough to make ends
meet
Have enough to make ends meet
Do not have enough to make ends meet
(reference)
Note. CI= confidence interval for odds ratio (OR).

0

Table 3.2. Summary of nonlinear regression analysis predicting medication adherence (continued)
Predictor

B

SE

p

OR

95% CI

Gender
Male
Female
(reference)

0.026

0.029

0

Note. CI= confidence interval for odds ratio (OR).

0.365

1.026

(0.970, 1.086)
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Chapter Four:
A moderated moderation of living arrangements and social support on the
relationship between depressive symptoms and medication adherence in patients
with heart failure
1. Introduction
There are 6.5 million patients in the United States with heart failure (HF) [1, 81].
In 2014 the costs associated with HF hospitalization were $11 billion [70].
Pharmacological treatment improves HF outcomes by optimizing cardiovascular function
and reducing HF symptoms [82]. Medication adherence is essential to improve health
outcomes [69], but the adherence rate of medications can be as low as 10% in patients
with HF [83].
2. Background
It is critical to identify factors contributing to medication adherence.
Psychological distress, particularly depressive symptoms, is a crucial predictor in
medication adherence affecting HF outcomes [27, 82, 84]. The prevalence of depressive
symptoms in patients with HF ranges from 15-60% [1, 84, 85]. According to a metaanalysis of 30 studies in chronic illness, patients with depressive symptoms were 1.76
times more likely to be nonadherent to medications than patients without depressive
symptoms [27]. In this meta-analysis of literature published between 1998 and 2009,
most studies used self-report or pharmacy records to assess medication adherence. Only
27% of the studies used electronic monitoring systems that provide accurate data on timedose or prescribed doses. Noticeably, only one study conducted in an HF population was
included in this meta-analysis [67]. That indicates a lack of research on medication
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adherence using objective measures in patients with HF. Studies in the last decades also
provide similar evidence about the association between depressive symptoms and
medication adherence in patients with HF by using various measures of depressive
symptoms, including the Patient Health Questionnaire [76, 80, 82], the Center for
Epidemiological Studies-Depression Scale [86], and the Medical Outcomes StudyDepression questionnaire [87]. However, an objective measure of medication adherence
was rarely used.
Living arrangement is generally defined as a status in which individuals live with
someone or lives alone [10]. The living arrangement is vital to someone with HF because
it represents their social and physical environment, and if others are in the household,
they can provide instrumental social support [10]. Instrumental social support is defined
as help or assistance tangibly or physically received by the patient. Examples include
picking up prescriptions or transportation [14]. Living with a spouse or a partner has also
been called structural social support. It has been defined as "the number and pattern of
direct and indirect social ties that surround the individual” [31]. There is evidence that
patients who live alone are more likely to report having high rates of depressive
symptoms and social isolation, and low medication adherence than patients who live with
a spouse [81, 88]. Wu and colleagues (2012) found that unmarried patients with HF were
more likely to be nonadherent to medications than married patients and were two times
more likely to have a cardiac-related event. However, inconsistent findings between
living arrangements and social support have been reported. Some of the inconsistencies is
due to the multiple types of social support measured [14, 31, 89]. In addition to the types
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discussed above, there are also, emotional social support which is defined as receiving
emotional support from others. [89] Some researchers have found living with a spouse
can provide high levels of support [28, 90] . In contrast, others have found that living
with family or spouse does not mean that patients always receive helpful support. For
example, George-Levi and colleagues (2016) reported that patients with a restricted
understanding of entitlement expect very little from their partner, and have higher rates of
medication nonadherence, as measured by a self-report instrument. However, the lowest
levels of medication adherence occurred in patients with high levels of restricted
entitlement with caregivers that have a compulsive caregiving style, that was described as
intrusive, poorly timed, and forced care that aims to be overinvolved in the patient's
problems to maintain proximity [39].
The interaction of different living arrangements with social support on the
relationship between depressive symptoms and medication adherence is not well
understood. We hypothesized that effect of living status on the association between
depressive symptoms and medication adherence depends on perceived social support.
Therefore, the specific aim of this study was to determine whether perceived social
support moderated the moderation effect of living arrangements on the association
between depressive symptoms and medication adherence.
3. Methods
3.1. Design Sample, and Setting
This secondary data analysis used baseline data collected from two studies of
patients with HF conducted at the University of Kentucky [67, 91]. The eligibility of
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participants in the two studies was the same. The eligible participants had confirmed
diagnoses of chronic HF and optimized their medical therapy for at least one month
before enrollment. Both studies excluded patients who had no coexisting terminal
illnesses. In this study, we selected a total of 209 participants with HF who had
completed data of interest in this study.
4. Measures
4.1. Depressive symptoms.
Depressive symptoms were measured by the Patient Health Questionnaire-9 (PHQ-9).
The PHQ-9 is a valid and reliable instrument used to assess depressive symptoms in
outpatient and inpatient settings [92]. Each question is rated using a Likert scale that
ranges from 0 (not at all) to 3 (nearly every day). A score of 10 or above is considered a
cut-off for depression; however, the scale can range from 0 to 27, with higher scores
indicating depression. Hammash and colleagues (2012) established reliability and
concurrent and construct validity of the PHQ-9 in HF patients. Construct validity was
established by comparing the PHQ-9 to the Beck Depression Inventory-II. The PHQ-9
demonstrated acceptable sensitivity and specificity in identifying depression. The ROC
was 0.91 (95% confidence interval, CI: 0.88-0.95).
4.2. Living arrangement.
Two items in demographic questionnaires collected the living arrangement on marital
status and living status. We categorized living arrangements into three categories: 1)
living with a spouse, 2) living with non-spousal family or friends, or 3) living alone.
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Although eight patients reported that they were married but living alone, we did not
include this group in the living arrangement category because of the small sample size in
this group.
4.3. Perceived social support.
Perceived social support is how emotionally supported a patient perceives they receive
support from family, friends, and significant others measured by the Multidimensional
Scale of Perceived Social Support (MSPSS). The 12-items on the instrument are rated on
a seven-point Likert scale that ranges from 1 (very strongly disagree) to 7 (very strongly
agree). Summed scores range from 12 to 84, with higher scores indicating higher
perceived support. There is no validated cut-point showing high or low perceived social
support. In this study, we used the upper tertile value of 79 as the cut-point so that onethird of participants fell into the high perceived social support group.
4.4. Medication adherence.
Medication adherence was defined as the percent of a prescribed HF medication (betablocker, ace inhibitor, diuretic) taken over three months measured by MEMS. Study
participants were then provided written and verbal instructions about using the MEMS
bottle, which medication to put in the bottle and closing the cap after each use. A MEMS
diary was provided to record all unscheduled MEMS caps openings. Patients returned the
MEMS bottle after 1 or 3 months of daily use of the MEMS device. The MEMS data
were downloaded and transferred into a database for analysis. Unscheduled cap openings
were excluded from the analysis based on the diary entries. Prior studies have
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demonstrated that MEMS is considered the benchmark for indirect medication adherence
[56]. Previous studies have also shown that using one medication in a MEMS bottle was
a sufficient indicator representative of all medication-taking behavior by study
participants [54, 55].
4.5. Demographic and clinical characteristics (e.g., age, gender, financial
status, education level, prescriptions, and New York Heart Association functional class
were collected using the structured questionnaires and medical records.
5. Procedures
Permission was received by the institutional review board at the University of
Kentucky to conduct both studies. Providers referred patients to the researchers, and fliers
were posted and set out in the cardiology clinic to recruit participants. After research
nurses screened participants' eligibility by reviewing medical records, they invited
eligible participants at their outpatient cardiology clinic visits by explaining the study
requirements to the eligible patients. Written consent was obtained. Patients completed
the questionnaires and were provided written and verbal instructions on how to use the
MEMS bottle. Patients were instructed to record the time and date of unscheduled cap
openings in a medication diary to increase the reliability of the data collected using the
MEMS. These events were excluded when the data was compiled. Patients used the
MEMS for three months, starting at enrollment. After the three months, patients returned
the MEMS to the researchers, and the data was downloaded using manufacturer-supplied
software. The MEMS data was then printed and entered into a data file for analyses [93].
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6. Data Analysis
Demographic and clinical characteristics were analyzed to describe sample
characteristics using descriptive statistics, including mean, standard deviation. One-way
analysis of variance with post hoc testing using the least significant difference was
conducted to determine differences in demographics among living arrangement groups.
We ran on a moderated moderation regression model using PROCESS macro Model 3 in
SPSS with bootstrapping of 5,000 samples to address the Specific Aim. Figure 1 presents
the conceptual diagram with depressive symptoms as the independent variable,
medication adherence as the dependent variable, living arrangement as a primary
moderator, and perceived social support as a secondary moderator. Figure 2 presents a
statistical diagram of the moderated moderation regression predicting outcomes of
medication adherence. PROCESS program generated dummy codes only for a multicategorial variable automatically. Thus, two dummy variables for the living arrangement
were generated by living with a spouse group as a reference group. We coded zero for
the low perceived social support group for the perceived social support. Significance of
three-way interaction (i.e., depressive symptoms [X], living arrangement [W], and
perceived social support [Z]) was determined by a 95% confidence interval. We created
a graph of the conditional Effect of depressive symptoms on medication adherence using
PROCESS's syntax.
7. Results
7.1 Sample characteristics.
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Of the 209 patients with HF (Table 1), most of the participants were Caucasian
(90%) and male (70%). The average age of the participant was 61 years old (SD = 12).
Patients with New York Heart Association functional class III/IV were 57% (n = 132).
Most of the participants reported having enough financially, with only 20% (n = 46)
reporting not having enough to make ends meet. More than half of the participants had
graduated from college or had advanced degrees (51%, n = 120), with 21% (n = 49) with
less than a high school education and 26% (n = 61) with high school education.
Half of the participants were married and lived with spouses (n=124, 53%); 19%
were living with a non-spouse, family, or friend (n = 45), and 29% lived alone (n=63).
Among the three groups, patients who lived with non-spousal family or friends reported
the highest levels of depressive symptoms (p = 0.03). Participants living with spouse
reported the highest levels of perceived social support (p ≤ .001).

7.2 Moderated moderation effects of social support and living arrangement on the
association between depressive symptoms and medication adherence
Table 2 presents the results of the moderated moderation regression using the
PROCESS. Depressive symptoms and two moderators (living arrangement and perceived
social support) explained 13.2% of the variance of medication adherence (F = 2.69, p
=.003). Among the predictors, only interaction among depressive symptoms, living alone
group (dummy variable with a reference group of living with a spouse), and perceived
social support significantly predicted medication adherence (b= -3.5019, p = 0.013). We
found that three-way interaction (X*W*Z: depressive symptom X living arrangement X
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perceived social support) was significant (p=.0324). It indicated that the Effect of
depressive symptoms on medication adherence was significantly moderated by the living
arrangement that was moderated by perceived social support.
Table 3 presents the conditional effect of two moderators on the association
between depressive symptoms and medication adherence. Figure 3 shows the
visualization of the dependent effects of two moderators on the associations. The effect of
depressive symptoms on medication adherence was significant only for two groups; the
living alone group who reported high levels of perceived social support and the living
with a non-spousal family group, who reported low levels of perceived social support. In
the living alone group who reported high levels of perceived social support, as their
depressive symptoms increased in one unit, their medication adherence decreased by 4.4
points (effect = -4.1855, p = .0021). Patients who lived with the non-spousal family
reported low levels of perceived social support; their depressive symptoms were also
inversely associated with medication adherence (effect = -1.0180, p = .0349).
However, for patients living with a spouse, depressive symptoms were not
associated with medication adherence regardless of whether they perceived high (p =
0.845) or low social support (p = 0.845). Patients living with a spouse sustained high
medication adherence (above 80%) even though their depressive symptoms were
increased. Besides, there was no significant association between depressive symptoms
and medication adherence for patients with a non-spousal family with high perceived
social support (p =0.1598) and patients living alone group who reported low levels of
perceived social support (p =0.0695).
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8. Discussion
We explored whether the association between depressive symptoms and
medication adherence was moderated by living arrangements and perceived social
support. We found that the moderation effect of living arrangement on the association
between depressive symptoms and medication adherence were dependent on perceived
social support. One of the compelling findings was that severe depressive symptoms were
strongly associated with decreasing medication adherence in patients who lived alone and
had high perceived social support levels. One possible explanation is that patients living
alone may lack practical or instrumental social support for medication adherence because
no one is available in their home, even though they reported high perceived social
support from their social network. Helpful instrumental support includes helping them to
set up pillboxes, reminding them to take pills on time by texting or calling, or picking up
prescriptions.[30]. The results indicate that patients living alone may require more
instrumental support. For example, tailoring text message medication reminders has
shown to be effective in increasing medication adherence. [94]
Another plausible explanation could be due to the measure of social support in
this study. We used the Multidimensional Scale of Perceived Social Support instrument
that generally assesses emotional social support rather than practical or instrumental
support for medication adherence. There are a few social support instruments that
measure practical and instrumental support. For example, the ENRICHD Social Support
Instrument includes emotional support as well as structural and practical support. [95]. A
structured support question asks if the participant is currently married or living with a
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partner. Practical social support was assessed using an item that asks if someone is
available to help with daily chores. The Medical Outcomes Study Social Support Survey
(MOS-SSS) also assesses perceived emotional support and tangible/instrumental support.
Four items for tangible/instrumental social support determine the availability of someone
who can help if you were confined to bed, needed to be taken to the doctor, have meals
prepared, or help with daily chores. Unfortunately, none of these instruments explicitly
ask about helping with medications. However, it does provide insight into how much
practical support is available to the patient, which could extend to picking up
prescriptions or filling pillboxes. Assessing instrumental social support may identify
possible gaps in the patient's support system that could decrease medication adherence.
Future research is needed to develop an instrument that evaluates perceived instrumental
support related to medication adherence and examine whether such instrumental support
predicts improving and sustaining medication adherence and decreasing hospitalization in
patients living alone.
Another notable finding was that the negative association between depressive
symptoms medication adherence was also significant for patients who lived with nonspousal family or friends but had low perceived social support. Future research could be
directed at exploring the reasons for co-habitation in patients without a spouse or partner.
There may be limited support from non-spousal family members for medication
adherence. This result may be explained by relationship quality between the patient and
family members. Bidwell and colleagues (2015) demonstrated that the patient-reported
quality of caregivers' relationship determined the patient's self-care maintenance
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(medication adherence). This study's results have important implications for clinicians
and researchers who work with patients with HF. Nurses must assess for depressive
symptoms, be aware of the living arrangements of patients, and inquire about social
support, in order to anticipate potential problems in medication adherence. If a patient is
having frequent emergency room visits or hospitalizations, assessing if the patient is
depressed, his or her living arrangement and perceived social support may help create a
plan so that interventions directed at treating depression or getting social service
consultations to get community assistance may assist in medication adherence and keep
the patient out of the hospital or ER. In this study, we did not assess the non-spousal
relationship of who the patients were living with or the relationship quality. In future
studies, asking the relationship may provide more information, leading to targeted
interventions at depressive symptoms and medication adherence.
9. Limitations
Although we included a sample of over 208 patients, a bigger sample size among
the living alone and lives with non-spousal family or friend group would have provided
more variance. However, we employed bootstrapping using 5000 samples which is a
method to overcome this type of limitation by using the study sample to randomly create
a sampling distribution that is a better estimate of what the true population would be..
Having a wider range of medication adherence across participants would have also been
informative.
10. Conclusions
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We demonstrated that the interaction of living arrangement and social support on
the relationship between depressive symptoms and medication depended was significant.
These results suggest that patients’ living arrangements and their perceived social support
are factors to be considered when evaluating medication adherence and when planning
care for a patient with depressive symptoms. Future research is needed to explore
whether the combined intervention of improving depressive symptoms and social support
interventions focusing on instrumental social support effectively increases medication
adherence.
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Table 4.1 Clinical and demographic characteristics of study participants
Variable
Total sample Living with
Living with
N=208
spousea
nonspousal familyb
n=124
N=45
Age, years
61±11.5
61±11.9
58±12.7
Gender- Female
male
74 (35)
32 (43)
22 (52)
134 (64)
86 (64)
20 (48)
Ethnicity
Caucasian
176 (85)
108 (87)
29 (64)
African-American
29 (14)
7 (6)
13 (29)
Asian
3 (1)
3 (3)
0 (0)
Education
Less than high school 41 (20)
21 (17)
11 (24)
High school graduate
Some college
57 (27)
30 (24)
13 (29)
College graduate or
above
60 (29)
31 (25)
15 (33)
48 (23)
35 (28)
3 (6)
NYHA class
1-2
3-4

58 (39)
89 (61)

31 (40)
46 (60)

10 (38.5)
16 (61.5)

Living alonec
N=54

p-value

62.6±10.7

0.158

20 (42)
28 (58)

0.008

39 (72)
9 (17)
0 (0)

0.001

9 (17)

.418

16 (30)
14 (26)
10 (19)
15 (40.5)
22 (59.5)

.144

Post-hoc,
P<.05

Table 4.1 Clinical and demographic characteristics of study participants (continued)
Variable

58

Finance
Have more than enough to make
ends meet
Have enough to make ends meet
Do not have enough to make
ends meet
Patient Health Questionnaire-9
Perceived social support
Prescribed numbers of doses
taken (%)
Days correct number of doses
taken (%)

Total
sample
N=208

Living with
spousea
n=124

Living with
nonspousal
familyb
N=45

Living
alonec
N=54

p-value

57 (27)

38 (31)

7 (16)

18 (33)

105 (50)

61 (49)

18 (40)

15 (28)

43 (21)
6.3±5.5
66.7±19.7

18 (14.5)
5.6±5.0
72.0±18.4

15 (33)
8.1±6.1
63.3±17.3

10 (19)
6.2±5.4
57.1±20.8

0.03
<0.001

90.4 (13.6)

92.3 (11.2)

86.3 (20.2)

87.8 (15.5)

0.032

82.8 (21.2)

85.1 (18.3)

79.6 (25.9)

78.0 (25.5)

0.112

Posthoc,
P<.05

.031

b>a
a>b &
c
a>b

Table 4.2. The conditional effects of depressive symptoms on medication adherence
W1 and W2: Dummy variables of the living arrangement and reference group are living with a spouse.

59

Predictors

b

se

p

95% CI Lower
bound

95% CI
Upper bound

Intercept
Depressive symptoms (X)
Lives with nonspousal famiy/friend (W1)
Lives alone (W2)
Depressive symptoms x Lives with nonspousal
family/friend (XW1)
Depressive symptoms x Lives alone (XW2)
Perceived social support (Z)
Depressive symptoms x Perceived social support
(XZ)
Lives with nonspousal family/friend x Perceived
social support (W1Z)
Lives alone x Perceived social support (W2Z)
Depressive symptoms x Lives with nonspousal
family/friend x Perceived social support (XW1Z)
Depressive symptoms x Lives alone x Perceived
social support (XW2Z)
Depressive symptoms x Living Arrangements x
Perceived social support (XWZ)

92.2
-0.060
4.64
0.376
-0.892

2.52
0.307
5.16
4.13
0.516

<.001
0.845
0.369
0.927
0.085

87.14
-0.666
-5.54
-7.77
-1.91

97.09
0.546
14.8
8.53
0.125

-0.637
2.403
-0.236

0.491
3.591
0.485

0.195
0.504
0.627

-1.605
-4.679
-1.19

0.329
9.487
0.721

-4.45

7.86

0.572

-19.94

11.05

7.99
0.3175

9.72
0.888

0.3146
0.7211

-7.642
-1.43

23.63
2.068

-3.50

1.39

0.0132

-6.262

-0.7418

0.0311

3.48

0.0324

Table 4.3. Conditional effect of depressive symptoms on medication adherence at each moderator group
Living arrangement

Perceived social

Effect

p

95% Lower CI

95% Upper CI

support
Lives with Spouse

Low

-0.060

0.8454

-0.6658

0.5458

Lives with Spouse

High

-0.2963

0.4315

-1.037

0.4450

Lives with non-spousal family or

Low

-0.9521

0.0227

-1.769

-0.1348

High

-0.8710

0.1598

-2.088

0.3463

Lives alone

Low

-0.6979

0.0695

-1.452

0.0563

Lives alone

High

-4.436

0.0005

-6.913

-1.959

friend
60

Lives with non-spousal family or
friend

61
Figure 4.1. The conceptual frame of the moderated moderation of living arrangement and perceived
social support on the relationship of depressive symptoms and medication adherence.
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Figure 4.2 Conceptual framework with the results of the moderated moderation analysis
The only predictor for medication adherence that was significant was the interaction of depressive symptoms*lives
alone*perceived social support. The test of highest order of unconditional interaction of depressive symptoms*living
arrangement*perceived social support explained about 3% of the variance of medication adherence.
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Figure 4.3 The conditional effect of depressive symptoms on medication adherence using perceived
social support with a high group cut off of >79 and the low group cut off of <79
For each one unit that depressive symptoms increased in patients living with non-spousal family with low perceived social
support decreased medication adherence by about one percent. For each one unit of depressive symptom increase in patients
living alone with high perceived social support, there was 4.4 percent decrease in medication adherence.

Chapter Five: Conclusions
1. Background and purpose
Medication is the primary treatment for patients with heart failure (HF), and it
remains a challenge for patients to stay adherent to the medication regimen. However,
medications control patients' symptoms. Among the reasons patients struggle with
medication adherence are medication regimen complexity, barriers such as forgetfulness
or feeling better, and factors such as depressive symptoms and perceived social support.
The purpose of this dissertation was to examine factors that affect medication
adherence in patients with HF in the context of their living arrangement. This chapter
included a summary and synthesis the findings from the 3 studies, a description of how
those results advance the state of the science in medication adherence, and
recommendations for practice and future research.
2. Summary of Findings
Chapter Two was a secondary data analysis of 130 patients with heart failure to
determine group differences across living arrangements in demographic, clinical
characteristics, and medication complexity and adherence and to determine if there was
an association between medication complexity and medication adherence, measured by a
medication event monitoring system (MEMS). For the nonlinear regression analysis,
there was no association between medication complexity and medication adherence. Due
to the lack of association, we could not perform a moderation analysis.
We did find the patients who live with a spouse had higher medication adherence
than the patients who lived with a non-spousal family or friend. There was no difference
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between the group who lived alone and the other groups. The patient group who lived
with non-spousal family or friends had a higher than expected rate of participants in the
'not enough to make ends meet' category. These findings suggest that future research
should determine reasons for lower medication adherence in the group who lives with a
non-spousal family or friend and develop and test interventions to promote adherence.
Chapter Three was a secondary data analysis of 206 patients with heart failure to
determine group differences across living arrangements in demographic and clinical
characteristics and barriers using the Barriers subscale of the Medication Adherence
Scale designed by Wu et al. (2008) to medication adherence using MEMS. We conducted
a nonlinear regression analysis to assess if there was an association between barriers and
medication adherence. There was no association, so we could not perform a moderation
analysis. Patient-reported barrier scores were low and medication adherence rates were
high across all groups. However, medication adherence was lower in the group who with
a non-spousal family member or friend than those who lived with a spouse. In contrast,
those who lived alone had similar adherence rates as those living with a spouse. Future
research should be directed understanding factors related to patients living with a nonspousal family member or friend having poorer medication adherence.
Chapter Four was a secondary data analysis of 208 patients with heart failure to
examine the association between depressive symptoms and medication adherence and
whether those relationships were moderated by living arrangement and levels of
perceived social support. Two moderator effects on the association between depressive
symptoms and medication adherence were examined. Medication adherence was assessed
using the prescribed dose taken determined by the MEMS as in previous chapters.
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Depressive symptoms were measured using the Patient Health Questionnaire-9 (PHQ-9),
and social support was measured using the Multidimensional Scale of Perceived Social
Support (MSPSS). A moderated moderation regression model was conducted using the
PROCESS macro version 3.5 (Model 3) in SPSS. The regression model included
depressive symptoms as the independent variable, medication adherence as the dependent
variable, living status as a primary moderator, and perceived social support as the
secondary moderator. We found that depressive symptoms and two moderators (i.e.,
living arrangement and perceived social support) explained 13.2% of the variance of
medication adherence. Among the predictors, only the interaction among depressive
symptoms, the living alone group, and perceived social support predicted medication
adherence. Three-way interaction (depressive symptom x living arrangement x perceived
social support) was significant. This indicated that the effect of depressive symptoms on
medication adherence was significantly moderated by living arrangement moderated by
perceived social support.
3. Impact of Dissertation on the State of the Science
We advanced the science by identifying that patients who live with non-spousal
family or friends have lower medication adherence rates than patients who live with
spouses. We also found that group had a higher number of participants who reported
they did not have enough money to make ends meet financial category, this may
factor into the living arrangement that they find themselves, but it also may serve as a
barrier to medication adherence, especially if they cannot afford some or all of their
medications. Our findings that medication adherence was lower in the group who
lives with nonspousal family or friends suggests they may not have quality social
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support in their living arrangement. In Chapter Three we found they had a higher
depressive symptoms than the other groups. The results suggest the group who live
with a non-spousal family member may be at higher risk for medication nonadherence that was previously recognized. Two factors that may make this group
more vulnerable are lower financial resources and depressive symptoms.
In Chapter Four, we demonstrated an the interaction among depressive symptoms,
living arrangement, and perceived social support which predicted medication
adherence. Patients with depressive symptoms who lived alone and had high
perceived social support had worse medication adherence. This finding appears
contrary to the expectation that emotional social support would buffer the effect of
depressive symptoms minimizing their effect on adherence. However, it may instead
suggest that other forms of social support such as instrumental support may be of
equal importance. Therefore, collecting information about living arrangement and
multiple types of social support are needed for promoting medication adherence,
particularly for patients with depressive symptoms.
4. Recommendations for nursing practice and research
Future researchers should examine why there is a difference in the medication
adherence rate of the group who lives with nonspousal family or friends and the other
groups. Designing and testing interventions to promote medication adherence
targeting medication complexity and living arrangement is warranted. Practical or
instrumental social support may be important promoting medication adherence and
should be assessed across living arrangements to determine if different types of
support are needed according to living arrangement. This will require the
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development of a practical social support instrument related to medication adherence
and one measuring practical medication barriers. More research to determine
differences in patients' psychological and social needs across living arrangements
would help determine if different interventions are needed depending on living
arrangement. This may be particularly important for patients with depressive
symptoms and low social support.
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